Modality
Degrader
MOA
PRMT5i
Target
BET
Pathway
PD-1/PD-L1
OCD
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
Aug 2023
→ Dec 2027
Phase 1Current
NCT04786748
1,385 pts·OCD
2023-08→2027-12·Recruiting
1,385 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-241.7y awayPh2 Data· OCD
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Recruit…
Catalysts
Ph2 Data
2027-12-24 · 1.7y away
OCD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04786748 | Phase 1/2 | OCD | Recruiting | 1385 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |